A5080706558- Urticaria and Related Conditions
- Dermatology and Skin Diseases
- Drug-Induced Adverse Reactions
- Food Allergy and Anaphylaxis Research
- Asthma and respiratory diseases
- Mast cells and histamine
- Autoimmune Bullous Skin Diseases
Novartis (India)
2022-2025
Background: Real-world data on the prevalence and burden of patients with chronic spontaneous urticaria (CSU) are limited in Japan. This study aimed to estimate CSU assess its humanistic economic burden. Methods: analysis utilized from Japanese adult respondents self-reporting physician-diagnosed collected through 2019 National Health Wellness Survey. The weighted 12-month was estimated using 2018 international census projections. Outcomes included SF-12v2 (physical mental component summary...
Patients with chronic urticaria (CU) may have different clinical courses of disease including periods active CU, remission, and relapse. The objective this study was to describe representative remission relapse profiles for patients CU. Adults a CU diagnosis confirmation diagnosis/CU-related treatment at least 6 weeks later were identified in the Optum® de-identified Electronic Health Record dataset (2007–2018). Active period during which patient not remission. Clinical defined as 12 months...
Abstract Background Skin diseases can have a significant impact on the physical, psychological and social well‐being of patients. Quantification burden chronic spontaneous urticaria (CSU) compared to other dermatological conditions is limited. Objectives To evaluate comparative humanistic economic CSU, atopic dermatitis (AD), psoriasis (PSO) in five European countries (EU5). Methods This cross‐sectional analysis data from adult respondents with physician diagnosis AD PSO 2020 National Health...